血小板生成素及受体MPL信号通路在髓系肿瘤中的研究进展  

Research progress of thrombopoietin/MPL signaling pathway in myeloid neoplasms

作　　者：张益敏 胡晓霞[1] ZHANG Yi-min;HU Xiao-xia(Department of Hematology,Changhai Hospital Affiated to Naval Military Medical University,Institute of Hematology of Chinese People’s Liberation Army,Shanghai 200433,China)

机构地区：[1]海军军医大学附属长海医院血液科中国人民解放军血液病研究所,上海200433

出　　处：《中国临床医学》2019年第2期281-285,共5页Chinese Journal of Clinical Medicine

基　　金：国家自然科学基金(81470321;81530047;81770160);上海市卫生系统优秀学科带头人培养计划(2017BR012)~~

摘　　要：血小板生成素(TPO)及其受体MPL信号通路不仅具有调节巨核细胞及血小板生成的作用,也参与调控造血干、祖细胞的增殖和分化。多项研究发现,TPO及MPL的异常表达会导致下游一系列信号通路异常,与多种髓系肿瘤的发生、发展和预后密切相关。TPO/MPL改变既可能是疾病的始动因素,也可能继发于其他改变。TPO/MPL能使白血病细胞休眠于骨髓龛中形成残留病灶,进而使其躲避化疗药物的杀伤。TPO受体激动剂艾曲泊帕能在改善血小板减少的同时,抑制白血病细胞的活性。本文对TPO/MPL信号通路的研究进展作一综述,以期帮助临床寻找治疗髓系肿瘤的新靶点。Thrombopoietin(TPO)and its receptor MPL signaling pathway not only plays an important role in regulating the formation of megakaryocytes and platelets,but also regulates the proliferation and differentiation of hematopoietic stem and progenitor cells.Studies have revealed that the aberrant expressions of TPO and MPL gene lead of chinese people’s Liberation Army to a series of abnormal signaling pathways,which are closely related to the myeloid neoplasms.The changes of TPO/MPL may be the initiating factor of the diseases,or resulted in disease relapse.TPO/MPL signaling pathway can hide leukemic cells in the bone marrow niche as residual lesion,protecting it from chemotherapy.The TPO receptor agonist,eltrombopag,can attenuate thrombocytopenia and inhibit the proliferation of leukemic cells.This article reviews the research progress of TPO/MPL signaling pathway in order to help the clinic find new targets for the treatment of myeloid tumors.

关 键 词：血小板生成素 血小板生成素受体 信号通路 急性髓细胞白血病 

分 类 号：R733.7[医药卫生—肿瘤]